With an enrollment target of 256 participants, this Phase 2/3 trial aims to elucidate the therapeutic potential of nafamostat, a potent TMPRSS2 inhibitor, in managing COVID-19-related lung complications, leveraging its anticoagulant and anti-pancreatitis properties observed in vitro and its approved use in cystic fibrosis treatment [111]. The gene discussed is TMPRSS2; the disease is COVID-19.